Basit öğe kaydını göster

dc.contributor.authorSipila, I
dc.contributor.authorBakker, B
dc.contributor.authorHagenas, L
dc.contributor.authorLindgren, AC
dc.contributor.authorOtten, B
dc.contributor.authorDarendeliler, F
dc.contributor.authorLarsson, P
dc.contributor.authorNeyzi, O
dc.contributor.authorPrice, AD
dc.date.accessioned2021-03-03T07:47:31Z
dc.date.available2021-03-03T07:47:31Z
dc.date.issued2003
dc.identifier.citationDarendeliler F., Larsson P., Neyzi O., Price A., Hagenas L., Sipila I., Lindgren A., Otten B., Bakker B., "Growth hormone treatment in Aarskog syndrome: Analysis of the KIGS (Pharmacia International Growth Database) data", JOURNAL OF PEDIATRIC ENDOCRINOLOGY & METABOLISM, cilt.16, sa.8, ss.1137-1142, 2003
dc.identifier.issn0334-018X
dc.identifier.othervv_1032021
dc.identifier.otherav_13f213d5-6a54-414e-bd8c-46e0b3b7c4b7
dc.identifier.urihttp://hdl.handle.net/20.500.12627/18819
dc.description.abstractAarskog syndrome is an X-linked disorder characterized by faciogenital dysplasia and short stature. The present study set out to determine the effect of growth hormone (GH) therapy in patients with Aarskog syndrome enrolled in KIGS - the Pharmacia International Growth Database.. Twenty-one patients (20 males) were evaluated. Median age at start of treatment was 8.3 years (10-90(th) percentiles, 5.1-14.1 years) and median height SDS was -2.8 (10-90(th) percentiles, -2.1 to -3.7). The median dose of GH was 0.22 mg/kg/week (10-90(th) percentiles, 0.15-0.30 mg/kg/week) given at a median frequency of six (4-7) times per week. Prepubertal patients were followed longitudinally for 1 year (n = 13) or 3 years (n = 7). After 1 year, the median height SDS had improved from -2.8 to -2.3 in 13 patients. After 3 years, height SDS had improved significantly (p <0.05) to -1.8 (10-90(th) percentiles, -2.1 to -1.1) in the seven patients. No adverse events were noted. Although final height data for these patients are still awaited, the present results support the use of GH to promote growth in children with Aarskog syndrome.
dc.language.isoeng
dc.subjectÇocuk Sağlığı ve Hastalıkları
dc.subjectİç Hastalıkları
dc.subjectEndokrinoloji ve Metabolizma Hastalıkları
dc.subjectSağlık Bilimleri
dc.subjectDahili Tıp Bilimleri
dc.subjectTıp
dc.subjectPEDİATRİ
dc.subjectKlinik Tıp (MED)
dc.subjectKlinik Tıp
dc.subjectENDOKRİNOLOJİ VE METABOLİZMA
dc.titleGrowth hormone treatment in Aarskog syndrome: Analysis of the KIGS (Pharmacia International Growth Database) data
dc.typeMakale
dc.relation.journalJOURNAL OF PEDIATRIC ENDOCRINOLOGY & METABOLISM
dc.contributor.department, ,
dc.identifier.volume16
dc.identifier.issue8
dc.identifier.startpage1137
dc.identifier.endpage1142
dc.contributor.firstauthorID169666


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster